FDA accepts new drug application from Melinta's Baxdela
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
CABP is pneumonia that is infected outside theMedical(http://facilityThe most common pathogens are streptococcus pneumoniae, haemophilus influenzae type flue goecole and atypical bacteria (e.gchlamydia pneumoniae, mycoplasma pneumoniae, Legionella)today, Melinta Therapeutics(http:// announcedthatFDA(http://accepted the company's application for a supplementarynew drug(http://(sNDA) for Baxdela (http:// and granted it priority review eligibilitythis sNDA application extends Baxdela's indications to treat community-acquired bacterial pneumonia (CABP)The FDA is expected to respond by October 24about baxdelaBaxdela is an innovative broad-spectrum antibiotic that has been approved by the FDA to treat acute bacterial skin and skin structure infections (ABSSSI)This antibiotic is effective against both gram-negative and positive bacteria, and can treat methicillin-resistant Staphylococcus aureus (MRSA)Baxdela has been awarded the fda for theof Theof Infectious DiseasesProducts (http://(QIDP)In thetrial(http://, patients with CABP were treated with Baxdela or moxifloxacinThe results show that Baxcela meets the non-disadvantage standard in efficacy compared with MoxishaAt the same time, Baxdela exhibits good safety and tolerance
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
